Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Clinical Trial ID NCT01614795

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Monoclonal antibodies in cancer therapy.	Oncoimmunology	2013	1.41
2	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.	Oncoimmunology	2014	1.05
3	Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.	Pediatr Blood Cancer	2014	0.90
4	Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.	Paediatr Drugs	2015	0.86
5	Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.	Cancer Discov	2015	0.86
6	Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.	Int J Mol Sci	2016	0.82
7	Bone sarcomas: from biology to targeted therapies.	Sarcoma	2012	0.82
8	Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.	Stem Cells Int	2016	0.81
9	Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.	Front Oncol	2013	0.79
10	Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.	Oncol Rev	2013	0.79
11	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.	Oncoimmunology	2015	0.77
12	Advances in paediatric cancer treatment.	Transl Pediatr	2014	0.76
13	Combining targeted therapeutics in the era of precision medicine.	Br J Cancer	2015	0.75